COX-2 inhibitor arthritis testing should include low-dose aspirin users, advisory cmte. says.
• By The Tan Sheet
COX-2 Rx ARTHRITIS AGENT TESTING SHOULD INCLUDE LOW-DOSE ASPIRIN USERS as a special subpopulation, FDA's Arthritis Advisory Committee agreed at a meeting on COX-2 inhibitor safety issues held in Gaithersburg, Md. March 24. Committee member David Yocum, MD, University of Arizona, said he is "concerned about combination therapies" after hearing data that regular low-dose aspirin use leads to a higher risk of gastrointestinal complications. COX-2 inhibitors also are suspected of causing GI problems. Believed to be the next generation of arthritis drugs, COX-2 agents act as anti-inflammatories through their selective inhibition of the cyclooxygenase-2 protein. Searle, Merck and Boehringer Ingelheim are developing COX-2 products for Rx sale.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.
With European biosimilars developers buoyed by recent regulatory moves, Medicines for Europe’s Isabell Remus and Julie Maréchal-Jamil discuss the next steps forward for the industry.